Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy (HCM is a complex, yet relatively common, genetic heart disease that occurs in approximately 1 in 500 individuals. It affects both genders and all races. The disease results in excessive thickening of the heart muscle—referred to as “hypertrophy”—which occurs most commonly in the septum (i.e. the muscular wall that separates the left and right lower chambers of the heart). In the majority of patients, this thickening begins during puberty, with little to no change in the thickness beyond early adulthood. However, symptoms from HCM can develop or worsen at any age, but most commonly occur during mid-life.

Doctors + Care Team

Carey D. Kimmelstiel, MD

Carey D. Kimmelstiel, MD

Loading ...

Accepting New Patients

Virtual Appointments Available

Title(s): Director, Interventional Cardiology Center; Professor, Tufts University School of Medicine
Department(s): Medicine, CardioVascular Center, Cardiology
Appt. Phone: 617-636-2273
Fax #: 617-636-5913

Interventional cardiology

View Full Profile for Carey D. Kimmelstiel, MD

Michael Robich, MD, MSPH

Michael Robich, MD, MSPH

Accepting New Patients

Title(s): Associate Surgical Director of the Hypertrophic Cardiomyopathy Center; Cardiac Surgeon; Assistant Professor, TUSM
Department(s): Surgery, CardioVascular Center, Cardiac Surgery
Appt. Phone: 617-636-5594
Fax #: 617-636-7175

Adult cardiac surgery, hypertrophic cardiomyopathy (HCM), structural heart disease, minimally invasive valve surgery, open and endovascular aortic procedures

View Full Profile for Michael Robich, MD, MSPH

Research + Clinical Trials


A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-G20 in Subjects with Hypertrophic Obstructive Cardiomyopathy

This will be a double-blinded, placebo-controlled study, aiming to assess the safety and tolerability of CT-G20 in subjects with obstructive hypertrophic cardiomyopathy (oHCM).
More information about research and clinical trials


A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients with Non-obstructive Hypertrophic Cardiomyopathy

This study is a double-blinded phase 2 clinical trial for a medication dedicated to treating patients with non-obstructive hypertrophic cardiomyopathy.
More information about research and clinical trials